Literature DB >> 18490252

Management of side effects of novel therapies for multiple myeloma: consensus statements developed by the International Myeloma Foundation's Nurse Leadership Board.

Page Bertolotti1, Elizabeth Bilotti, Kathleen Colson, Kathleen Curran, Deborah Doss, Beth Faiman, Maria Gavino, Bonnie Jenkins, Kathy Lilleby, Ginger Love, Patricia A Mangan, Emily McCullagh, Teresa Miceli, Kena Miller, Kathryn Rogers, Sandra Rome, Stacey Sandifer, Lisa C Smith, Joseph D Tariman, Jeanne Westphal.   

Abstract

Nurses play an essential role in managing the care of patients with multiple myeloma, who require education and support to receive and adhere to optimal therapy. The International Myeloma Foundation created a Nurse Leadership Board comprised of oncology nurses from leading cancer centers and community practices. An assessment survey identified the need for specific recommendations for managing key side effects of novel antimyeloma agents. Myelosuppression, thromboembolic events, peripheral neuropathy, steroid toxicities, and gastrointestinal side effects were selected for the first consensus statements. The board developed recommendations for healthcare providers in any medical setting, including grading of side-effect toxicity and strategies for managing the side effects in general, with specific recommendations pertaining to the novel agents.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18490252      PMCID: PMC4020240          DOI: 10.1188/08.CJON.S1.9-12

Source DB:  PubMed          Journal:  Clin J Oncol Nurs        ISSN: 1092-1095            Impact factor:   1.027


  12 in total

1.  Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma.

Authors:  S Vincent Rajkumar; Suzanne R Hayman; Martha Q Lacy; Angela Dispenzieri; Susan M Geyer; Brian Kabat; Steven R Zeldenrust; Shaji Kumar; Philip R Greipp; Rafael Fonseca; John A Lust; Stephen J Russell; Robert A Kyle; Thomas E Witzig; Morie A Gertz
Journal:  Blood       Date:  2005-08-23       Impact factor: 22.113

Review 2.  Multiple myeloma.

Authors:  Robert A Kyle; S Vincent Rajkumar
Journal:  N Engl J Med       Date:  2004-10-28       Impact factor: 91.245

3.  Thalidomide and dexamethasone: a new standard of care for initial therapy in multiple myeloma.

Authors:  Paul Richardson; Kenneth Anderson
Journal:  J Clin Oncol       Date:  2005-12-19       Impact factor: 44.544

Review 4.  The emerging role of novel therapies for the treatment of relapsed myeloma.

Authors:  Paul G Richardson; Teru Hideshima; Constantine Mitsiades; Kenneth C Anderson
Journal:  J Natl Compr Canc Netw       Date:  2007-02       Impact factor: 11.908

Review 5.  Clinical impact of bortezomib in frontline regimens for patients with multiple myeloma.

Authors:  Rami Manochakian; Kena C Miller; Asher A Chanan-Khan
Journal:  Oncologist       Date:  2007-08

6.  Peripheral neuropathy associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board.

Authors:  Joseph D Tariman; Ginger Love; Emily McCullagh; Stacey Sandifer
Journal:  Clin J Oncol Nurs       Date:  2008-06       Impact factor: 1.027

7.  Myelosuppression associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board.

Authors:  Teresa Miceli; Kathleen Colson; Maria Gavino; Kathy Lilleby
Journal:  Clin J Oncol Nurs       Date:  2008-06       Impact factor: 1.027

8.  Thromboembolic events associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board.

Authors:  Sandra Rome; Deborah Doss; Kena Miller; Jeanne Westphal
Journal:  Clin J Oncol Nurs       Date:  2008-06       Impact factor: 1.027

9.  Steroid-associated side effects in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board.

Authors:  Beth Faiman; Elizabeth Bilotti; Patricia A Mangan; Kathryn Rogers
Journal:  Clin J Oncol Nurs       Date:  2008-06       Impact factor: 1.027

Review 10.  Understanding novel therapeutic agents for multiple myeloma.

Authors:  Joseph D Tariman
Journal:  Clin J Oncol Nurs       Date:  2003 Sep-Oct       Impact factor: 1.027

View more
  4 in total

1.  Overview and experience of a nursing e-mentorship program.

Authors:  Beth Faiman
Journal:  Clin J Oncol Nurs       Date:  2011-08       Impact factor: 1.027

2.  Survivorship care guidelines for patients living with multiple myeloma: consensus statements of the International Myeloma Foundation Nurse Leadership Board.

Authors:  Elizabeth Bilotti; Beth M Faiman; Tiffany A Richards; Joseph D Tariman; Teresa S Miceli; Sandra I Rome
Journal:  Clin J Oncol Nurs       Date:  2011-08       Impact factor: 1.027

3.  Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: findings using real-world claims data.

Authors:  April Teitelbaum; Abbie Ba-Mancini; Hui Huang; Henry J Henk
Journal:  Oncologist       Date:  2013-01-08

4.  Peripheral neuropathy associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board.

Authors:  Joseph D Tariman; Ginger Love; Emily McCullagh; Stacey Sandifer
Journal:  Clin J Oncol Nurs       Date:  2008-06       Impact factor: 1.027

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.